health
Antifungal Effect
An antifungal effect refers to activity against fungi, meaning a substance may inhibit or act against fungal organisms such as Candida, Aspergillus, or dermatophytes. It describes antifungal activity rather than a symptom a person necessarily notices.
Learn more about the Antifungal Effect health topic.
These are research findings, not promises. Most options have little evidence, and results differ from person to person.
What may help
None of these options has good evidence yet. Best evidence first.
1 option:1 not enough evidence
Oil PullingpracticeNot enough evidence
Too few or too small studies to know if it works.
All 2 studies with a clear result found a benefit. Strongest study: a randomized controlled trial.
A randomized trial in people with cancer found fewer Candida colonies after treatment, with a mean difference of -29.27 colony count. In a cohort of 3 people, oil pulling reduced C. albicans by about 84%, compared with about 57% with saline.
Open the Oil Pulling page
The expert view shows every study, dose protocol and source.
What may help
Linked to improving it1 listedStart here
The best we have, but the evidence is still weak
- →PracticesOil PullingCertaintyLowSourceClinical3 other sources
A randomized trial in people with cancer found fewer Candida colonies after treatment, with a mean difference of -29.27 colony count. In a cohort of 3 people, oil pulling reduced C. albicans by about 84%, compared with about 57% with saline.
Who was studied
- Healthy people and patients
- Cancer
Open Oil PullingStudy result
A highly significant reduction (p = 2.3 × 10^–39) in the number of Candida colonies was observed in the treatment arm when comparing pre- and post-study results.
How to read the evidence
Evidence tier — overall strength of the evidence for the whole compound
- StrongWell established — backed by strong, consistent human research.
- ModerateSome genuine support, but mostly from small or lower-quality studies. Promising, not proven.
- PreliminaryEarly-stage evidence — a promising hypothesis, not an established effect yet.
- LimitedVery limited evidence — treat this as a hypothesis, not proof.
- InsufficientNot enough good evidence to draw conclusions yet.
Certainty — how sure we can be that the effect is real
- Very highVery sure — strong, consistent evidence
- HighFairly sure — consistent evidence from good studies
- MediumModerately sure — new studies could change this
- LowNot sure — little or mixed evidence
- Very lowVery unsure — almost no usable evidence
Source — where the data comes from
- Meta-analysisPooled analysis of many trials — the strongest evidence
- RCTRandomized controlled trial — a strong human study design
- ClinicalA human clinical study
- Reference knowledgeFrom general health-science or pharmacology references, not a study of this exact claim
- Animal researchStudied in animals, not humans
- Community reportsAggregated user reports — anecdotal signal, not evidence
- TheoreticalMechanism-based reasoning, not yet tested
Study grade — quality of each underlying study (A best, D weakest)
- AHigh-quality — strong, consistent human trials
- BGood — solid evidence with some limitations
- CModerate — limited, small, or mixed-quality studies
- DWeak — preliminary, indirect, or animal-only
Confidence — how strongly the sources back a finding
A 0–100 score from study quality and agreement
Most supplement evidence is graded C–D. Read it as preliminary signal, not proof.
Full write-up
What is it
An antifungal effect refers to activity against fungi, meaning a substance may inhibit or act against fungal organisms such as Candida, Aspergillus, or dermatophytes. It describes antifungal activity rather than a symptom a person necessarily notices.
This outcome is not the same as a confirmed clinical cure or proof that a person’s fungal infection will clear. The listed findings concern antifungal activity reported in pharmacology references or reviews, without human evidence establishing the effect in people.
How interventions help
The interventions linked with this outcome are supported mainly by pharmacology, microbiology, or in vitro findings rather than demonstrated human antifungal treatment effects. Across several options, the reported activity involves constituents acting against Candida and, in some cases, Aspergillus or dermatophytes. These findings indicate laboratory activity, but they do not establish that an oral or topical intervention will treat an infection in people.
Practical use also differs. Oregano Oil is associated with a typical dose of 100-200mg standardized extract and a typical duration of 2-4 weeks, while MCT Oil is described using 1-3 g caprylic acid/day and both acute and chronic use. Garlic has been evaluated over 14 days. These durations describe how an intervention was characterized or studied, not a confirmed time to benefit, and no established onset or persistence after stopping is provided.
The main distinction is therefore between laboratory antifungal activity and clinical effectiveness. The available findings do not establish which option is most effective for a particular fungal condition, whether continuous use is necessary, or whether effects continue after an intervention is stopped. They also do not define applicability by health status, since the interventions are not specified as having been studied in a particular health group.
Choosing guidance
These options are not directly interchangeable. The evidence is mainly based on pharmacology references and laboratory findings rather than clinical studies in people. Garlic is supported by a narrative review, but the comparison does not provide human evidence for the listed options with a human-evidence assessment. Readers seeking evidence from human treatment studies should therefore treat these findings as preliminary rather than as established clinical effectiveness.
Information about amount and duration is uneven across the options, so the entries cannot be fairly compared by regimen. The summaries also do not establish how quickly any option might produce an antifungal effect. A stated study period or experimental regimen should not be interpreted as a validated treatment schedule.
The options may be most relevant to someone reviewing laboratory or pharmacology signals and willing to recognize the uncertainty around their clinical relevance. They are less suitable as a basis for choosing between treatments when human evidence, a predictable time to effect, or a directly comparable course is important. The summaries do not provide enough consistent comparative evidence to determine whether one option performs better than another or whether findings would apply to a particular person, type of fungal infection, or health status.